sglt2 inhibitors and glp-1 receptor agonists Illustration of potential synergistic effects of inhibitor with SGLT2 Inhibitors vs. GLP-1 Agonists

How Are Key Players Competing in the GLP-1 Receptor Agonist Market

However, Novo Nordisk is expected to emerge as the leading company, having a large portfolio of GLP1 drugs, and is expected to capture 55 per cent of the market share in 2029.

If a patient receiving subcutaneous semaglutide 0.5 mg once weekly is to be switched to once-daily oral semaglutide, they should initiate a 7-mg or 14-mg dose up to 17 days after their last injection (7)

Kubota, S., Liu, Y., Iizuka, K., Kuwata, H., Seino, Y., & Yabe, D

NA, not applicable

The NF-B and MAPK signaling pathways were blocked by Liraglutide, which ultimately reduced the expression of nuclear factor of activated T cells (NFATc1)